entinostat has been researched along with Lymphoma, B-Cell in 3 studies
Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Entinostat is an orally bioavailable class I HDAC inhibitor with a long half-life, which is under evaluation in haematological and solid tumour malignancies." | 5.42 | Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. ( Barth, MJ; Czuczman, MS; Frys, S; Gu, JJ; Hernandez-Ilizaliturri, FJ; Hu, Q; Mavis, C; Simons, Z; Skitzki, J; Song, L, 2015) |
| "Entinostat is an orally bioavailable class I HDAC inhibitor with a long half-life, which is under evaluation in haematological and solid tumour malignancies." | 1.42 | Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. ( Barth, MJ; Czuczman, MS; Frys, S; Gu, JJ; Hernandez-Ilizaliturri, FJ; Hu, Q; Mavis, C; Simons, Z; Skitzki, J; Song, L, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lai, MJ | 1 |
| Ojha, R | 1 |
| Lin, MH | 1 |
| Liu, YM | 1 |
| Lee, HY | 1 |
| Lin, TE | 1 |
| Hsu, KC | 1 |
| Chang, CY | 1 |
| Chen, MC | 1 |
| Nepali, K | 1 |
| Chang, JY | 1 |
| Liou, JP | 1 |
| Simmons, JK | 1 |
| Patel, J | 1 |
| Michalowski, A | 1 |
| Zhang, S | 1 |
| Wei, BR | 1 |
| Sullivan, P | 1 |
| Gamache, B | 1 |
| Felsenstein, K | 1 |
| Kuehl, WM | 1 |
| Simpson, RM | 1 |
| Zingone, A | 1 |
| Landgren, O | 1 |
| Mock, BA | 1 |
| Frys, S | 1 |
| Simons, Z | 1 |
| Hu, Q | 1 |
| Barth, MJ | 1 |
| Gu, JJ | 1 |
| Mavis, C | 1 |
| Skitzki, J | 1 |
| Song, L | 1 |
| Czuczman, MS | 1 |
| Hernandez-Ilizaliturri, FJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Chidamide Combined With VDDT Regimen（Vinorelbine，Liposomal Doxorubicin，Dexamethasone and Thalidomide） in Relapse and Refractory Patients With Diffuse Large B Cell Lymphoma[NCT02733380] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for entinostat and Lymphoma, B-Cell
| Article | Year |
|---|---|
1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
Topics: A549 Cells; Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Catalytic Do | 2019 |
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.
Topics: Animals; Benzamides; Cell Line, Tumor; Histone Deacetylase Inhibitors; Humans; Lymphoma, B-Cell; Mec | 2014 |
Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apo | 2015 |